Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Mariagrazia LorenzinAugusta OrtolanGiacomo CozziAntonia CalligaroMaria FavaroTeresa Del RossAndrea DoriaRoberta RamondaPublished in: Clinical rheumatology (2021)
Survival rate was good for anti-TNFα and other bDMARDs. Female sex was a predictor of first bDMARD discontinuation, unlike mechanism of action, comorbidities, and BMI. Key Points • Drug survival in PsA patients was confirmed be greater for the first bDMARD administered. • In case of failure of the first bDMARD, switching/swapping proved a good treatment option, as reflected by a persistent satisfactory effectiveness with second-line bDMARDs and so subsequent switches. • Female sex may constitute a predisposing risk factor for flare and therapeutic switches. • Discontinuation or switching of biologics due to mechanism of action, comorbidities tolerability and BMI did not seem to impact first bDMARD withdrawal.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- body mass index
- newly diagnosed
- randomized controlled trial
- systematic review
- chronic kidney disease
- emergency department
- clinical trial
- weight gain
- radical prostatectomy
- open label
- free survival
- patient reported
- electronic health record
- patient reported outcomes
- double blind